# A Phase 3 Trial in Advanced Epithelioid Mesothelioma

Source: https://onco.cc/trials/nct07824986/  
OnCo record `nct07824986` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of VT3989 run by Vivace Therapeutics, Inc, not yet recruiting.

## Summary

A Phase 3 Trial in Advanced Epithelioid Mesothelioma is a phase 3 interventional study registered as NCT07824986 by Vivace Therapeutics, Inc, with 350 participants planned, started 2026-12-01, primary completion expected 2028-05-01. Conditions recorded: Pleural Mesothelioma, Mesothelioma. Interventions recorded: VT3989, gemcitabine, Vinorelbine.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07824986
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label Trial Comparing VT3989 Versus Gemcitabine or Vinorelbine in Participants With Advanced Epithelioid Mesothelioma, Who Previously Received Platinum-Based Systemic Chemotherapy and Immunotherapy
- Sponsor: Vivace Therapeutics, Inc
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT07824986: https://clinicaltrials.gov/study/NCT07824986

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Pleural mesothelioma](https://onco.cc/cancers/pleural-mesothelioma/)
- drugs: [VT3989](https://onco.cc/drugs/vt3989/)
- companies: [Vivace Therapeutics](https://onco.cc/companies/vivace-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07824986.json